Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger StuppCentre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, SwitzerlandMonika E. HegiUniversity Hospital of LausanneWarren MasonUniversity of TorontoMartin J. van den BentDaniel de Hoed Cancer Centre/Erasmus Medical Centre, Rotterdam, NetherlandsMartin TaphoornUniversity Medical Centre, Utrecht, NetherlandsRobert C. JanzerUniversity Hospital of LausanneSamuel K. LudwinQueens University, Kingston, Ontario, CanadaAnouk AllgeierEuropean Organisation for Research and Treatment of Cancer, Brussels, BelgiumBarbara FisherUniversity of Western Ontario, London, Ontario, CanadaKarl BélangerHôpital Notre Dame du Centre Hospitalier Universitaire, Montreal, Quebec, CanadaPeter HauAlba A. BrandesJohanna M. M. GijtenbeekUniversity Medical Centre St Radboud, Nijmegen, NetherlandsChristine MarosiMedical University of Vienna, Vienna, AustriaCharles J. VechtDaniel de Hoed Cancer Centre/Erasmus Medical Centre, Rotterdam, NetherlandsKarima MokhtariHôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale UMR711, Groupe Hospitalier Pitié-Salpêtrière, Paris, FrancePieter WesselingUniversity Medical Centre St Radboud, Nijmegen, NetherlandsS. VillàDuran i Reynals HospitalElizabeth A. EisenhauerNational Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, CanadaThierry GorliaEuropean Organisation for Research and Treatment of Cancer, Brussels, BelgiumMichael WellerUniversity of Tübingen Medical School, Tübingen, GermanyDenis LacombeEuropean Organisation for Research and Treatment of Cancer, Brussels, BelgiumJ. Gregory CairncrossUniversity of Calgary, Calgary, Alberta, CanadaRené‐Olivier MirimanoffUniversity Hospital of Lausanne
2009en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
3 ta iqtibos0 ta foydalanilgan manba